£89.50
This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.
Resistance to Targeted Therapies in Lymphomas
Resistance of Targeted Therapies Excluding Antibodies for Lymphomas
Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
Resistance to Targeted Therapies in Multiple Myeloma
Resistance to Molecular Therapies for Hepatocellular Carcinoma
Resistance in Hematologic Malignancies and Cancer
Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives
Resistance to Targeted Therapies in Breast Cancer
Current Applications for Overcoming Resistance to Targeted Therapies
Mechanisms of Drug Resistance in Cancer Therapy
Cancer Drug Resistance
Drug Resistance in Oncology